trending Market Intelligence /marketintelligence/en/news-insights/trending/3ywzccwdjbu4sojtzkg3vw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

NeuroVive licenses chemistry for inherited vision loss treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

NeuroVive licenses chemistry for inherited vision loss treatment

Sweden's NeuroVive Pharmaceutical AB said it licensed chemistry for its Leber's hereditary optic neuropathy treatment to California-based BridgeBio Pharma LLC.

The deal, which has a total transaction value of about $60 million, covers a subset of succinate prodrug chemistry under NeuroVive's NVP015 clinical program. The amount includes research funding, milestone payments and royalties.

Leber's hereditary optic neuropathy, or LHON, is a genetic condition that causes loss of vision.

BridgeBio said it launched a unit, called Fortify Therapeutics, to further develop the chemistry it acquired for use as local treatment of LHON, with an initial financial commitment of $20 million.

NeuroVive said development of NVP015 for other mitochondrial disorders will continue.